ALNY has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALNY has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alnylam Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-106 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-312 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Alnylam Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -42.67%. Alnylam Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -58.48%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.83%.
The historical data trend for Alnylam Pharmaceuticals's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EBIT | Get a 7-Day Free Trial | -885.25 | -771.10 | -709.12 | -971.03 | -312.30 |
Alnylam Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EBIT | Get a 7-Day Free Trial | -177.11 | -143.41 | -244.17 | 181.63 | -106.35 |
For the Biotechnology subindustry, Alnylam Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-312 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alnylam Pharmaceuticals (NAS:ALNY) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Alnylam Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:
ROC % (Q: Dec. 2023 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2023 ) | + | Invested Capital (Q: Dec. 2023 )) | / count ) |
= | -465.616 * ( 1 - -0.13% ) | / | ( (1016.472 | + | 1168.607) | / 2 ) |
= | -466.2213008 | / | 1092.5395 | |||
= | -42.67 % |
where
Invested Capital | (Q: Sep. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 3839.073 | - | 786.934 | - | ( 2406.278 | - | max(0, 949.785 | - | 2985.452 | + | 2406.278 | )) |
= | 1016.472 |
Invested Capital | (Q: Dec. 2023 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 3829.88 | - | 646.362 | - | ( 2439.382 | - | max(0, 967.786 | - | 2982.697 | + | 2439.382 | )) |
= | 1168.607 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.
2. Joel Greenblatt's definition of Return on Capital:
Alnylam Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:
ROC (Joel Greenblatt) % | (Q: Dec. 2023 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Sep. 2023 | Q: Dec. 2023 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -425.396 | / | ( ( (729.076 + max(-329.095, 0)) | + | (725.789 + max(-382.961, 0)) ) | / | 2 ) |
= | -425.396 | / | ( ( 729.076 | + | 725.789 ) | / | 2 ) |
= | -425.396 | / | 727.4325 | ||||
= | -58.48 % |
where Working Capital is:
Working Capital | (Q: Sep. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (325.445 | + | 95.771 | + | 157.958) | - | (786.934 | + | 77.14 | + | 44.195) |
= | -329.095 |
Working Capital | (Q: Dec. 2023 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (327.787 | + | 89.146 | + | 126.382) | - | (646.362 | + | 102.753 | + | 177.161) |
= | -382.961 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Alnylam Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Dec. 2023 ) |
= | -312.296 | / | 17038.436 | |
= | -1.83 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Michael W Bonney | director | 65 HAYDEN AVE, LEXINGTON MA 02421 |
Pushkal Garg | officer: CMO & EVP Dev & Med Affairs | C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472 |
Akshay Vaishnaw | officer: SVP, Clinical Research | 300 THIRD STREET, CAMBRIDGE MA 02139 |
Yvonne Greenstreet | officer: EVP, Chief Commercial Officer | PACIRA PHARMACEUTICALS, INC., 5 SYLVAN WAY, PARSIPPANY NJ 07054 |
Jeffrey V. Poulton | officer: Chief Financial Officer | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Tolga Tanguler | officer: EVP, Chief Commercial Officer | 675 WEST KENDALL STREET, HENRI A. TERMEER SQUARE, CAMBRIDGE MA 02142 |
Indrani Lall Franchini | officer: EVP, CLO & Secretary | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
Peter N Kellogg | director | MERCK & CO., INC, ONE MERCK DRIVE., P.O. BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
Carolyn R Bertozzi | director | LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285 |
Dennis A Ausiello | director | PFIZER INC ATTN CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Charles Elliott Sigal | director | 32 BREARLY ROAD, PRINCETON NJ 08540 |
Phillip A Sharp | director | BIOGEN INC LEGAL DEPARTMENT, 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
John Maraganore | director, officer: President and CEO | 75 SIDNEY ST, CAMBRIDGE MA 02139 |
Laurie Keating | officer: SVP,GC & Secretary | 300 THIRD STREET, CAMBRIDGE MA 02142 |
Steven M Paul | director | C/O ELI LITTY & CO, LIIY CORPORATE CENTER DC 1093, INDIANAPOLIS IN 46285 |
From GuruFocus
By Marketwired • 10-17-2023
By Business Wire • 01-09-2024
By Marketwired • 10-19-2023
By Marketwired • 11-02-2023
By Business Wire • 10-19-2023
By Business Wire • 09-06-2023
By Business Wire • 11-07-2023
By Business Wire • 09-13-2023
By Business Wire • 01-02-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.